Trust Signals
Key Takeaways
- Injection-site reactions (pain, erythema, induration) are the most consistently reported SS-31 side effects across human trials, including in the MMPOWER and PROGRESS-HF programs.
- SS-31, known clinically as elamipretide, has been studied in Phase I through Phase III trials; it is not FDA approved as of May 2026, following a Complete Response Letter in 2023 for the Barth syndrome NDA.
- The tetrapeptide targets cardiolipin on the inner mitochondrial membrane via electrostatic and aromatic interactions, a mechanism distinct from generic antioxidants, but a precise mechanism does not automatically confer safety in long-term use.
- Purity matters more than commodity pages acknowledge: an SS-31 vial without HPLC purity above 98%, mass spec confirmation, and endotoxin data cannot be assumed safe to inject.
- Long-term systemic safety data beyond 12 months of continuous human use is limited; extrapolating from animal data or short trials to multi-year use is not supported by current evidence.
What Are SS-31 Peptide Side Effects? (Direct Answer)
Table of Contents
- Evidence Ledger: Graded Claims on SS-31 Side Effects
- What Is SS-31 and Why Does the Mechanism Matter for Safety?
- What Human Trial Safety Data Actually Shows
- What Most Pages Get Wrong About SS-31 Side Effects
- Injection-Site Reactions: Frequency, Severity, and Management
- Systemic Safety: Heart, Kidney, and Liver Signal Review
- Formulation and Stability: The Hidden Risk Factor
- Honest Head-to-Head: SS-31 vs. Alternatives for Mitochondrial Support
- Operational Label Literacy: How to Read an SS-31 COA
- Who Should Not Use SS-31
- FAQ
- Sources
Evidence Ledger: Graded Claims on SS-31 Side Effects
| Claim | Best Evidence Type | Effect Direction | Confidence |
|---|---|---|---|
| Injection-site reactions are the dominant adverse effect | Human RCT (MMPOWER-3, PROGRESS-HF) | Consistent finding | High |
| Systemic adverse events are infrequent and mild | Human RCT / Phase II data | Low systemic signal | Moderate |
| No established renal or hepatic toxicity | Phase II/III trial safety reporting | No signal to date | Moderate (limited duration) |
| Cardiolipin binding reduces cytochrome c release | Biochemical/mechanistic studies, in vitro | Protective direction | Moderate (mechanism, not clinical outcome) |
| Long-term safety beyond 12 months | No human data published | Unknown | Very Low |
| Safety of research-compound SS-31 outside clinical oversight | No controlled data | Unknown | Very Low |
| Drug interactions with common medications | No formal human interaction studies | Unknown | Very Low |
| Safety in pregnancy or lactation | No adequate human data | Unknown, not supported | Very Low |
What Is SS-31 and Why Does the Mechanism Matter for Safety?
SS-31 (elamipretide, also designated MTP-131 or Bendavia in earlier literature) is a synthetic tetrapeptide with the sequence D-Arg-2'6'-dimethylTyr-Lys-Phe-NH2. It is four amino acids long with a molecular weight of approximately 638.8 g/mol for the free base form.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →The safety-relevant mechanism centers on two features: an alternating aromatic-cationic motif that allows the peptide to accumulate selectively at the inner mitochondrial membrane, and a specific electrostatic affinity for cardiolipin, a phospholipid unique to that membrane. Haney et al. and work from the Bharat Bhatt-led PROGRESS team have described how this cardiolipin binding stabilizes electron transport chain complexes and reduces the release of cytochrome c, a pro-apoptotic signal.
Why the mechanism matters for your safety question: A cardiolipin-targeting peptide theoretically affects mitochondrial dynamics in every cell type, not just diseased tissue. That breadth is why the absence of a detected toxicity signal in short trials is encouraging but not fully reassuring for long-term use across diverse tissues.
What Human Trial Safety Data Actually Shows
The most reliable safety data come from three program contexts:
MMPOWER-3 (Mitochondrial Myopathy Primary Outcome Research trial, Phase III): This trial enrolled patients with primary mitochondrial myopathy and used subcutaneous elamipretide 40 mg per day over 24 weeks. The primary efficacy outcome was not met. The published safety profile documented injection-site reactions as the most common adverse event. Rates of serious adverse events were not significantly elevated versus placebo in the reported data.
PROGRESS-HF (Phase II in heart failure with preserved ejection fraction): A smaller randomized trial using subcutaneous elamipretide. Injection-site adverse events were again the dominant finding. No signals in hepatic enzymes or renal function markers were highlighted in the published results.
TAZPOWER (Barth syndrome, Phase II/III): Involved a pediatric and young-adult population. Injection-site reactions remained the leading adverse event category.
Across these programs, the pattern is consistent: local tolerability is the primary challenge; systemic organ toxicity has not emerged as a clear signal in trials lasting weeks to months. However, none of these trials were designed or powered as primary safety studies, and enrollment sizes ranged from roughly 12 to 218 participants, which limits the ability to detect rare adverse events occurring in fewer than roughly 1 in 50 people.
What Most Pages Get Wrong About SS-31 Side Effects
Here is what those pages omit:
- Trial safety data applies to pharmaceutical-grade elamipretide under clinical supervision, not to research peptides from compounding or synthesis sources. A vial purchased outside a supervised clinical program may contain endotoxins, truncated sequences, or oxidized fragments. Injecting those impurities carries risks completely separate from the peptide's own pharmacology.
- The MMPOWER-3 trial did not meet its primary endpoint. Pages promoting SS-31 for mitochondrial disease often cite the favorable safety profile without noting that efficacy was not established in the largest trial to date. A safe compound that does not work as expected in its intended population is still a compound you are taking a risk with for uncertain benefit.
- Injection-site frequency is consistently underquoted. In some trial arms, injection-site reactions affected a majority of participants. "Mild" does not mean uncommon.
- The regulatory history matters. The FDA issued a Complete Response Letter for the Barth syndrome NDA in 2023. Citing pre-NDA enthusiasm as current regulatory status is inaccurate.
Injection-Site Reactions: Frequency, Severity, and Management
Injection-site reactions with SS-31 follow a pattern common to many subcutaneous peptides. The tetrapeptide is positively charged at physiological pH (its alternating cationic residues carry net positive charge), which promotes interaction with negatively charged components of subcutaneous tissue and may contribute to local irritation.
Published trial summaries describe the reactions as pain at injection, localized erythema (redness), and induration (hardening). These effects were generally self-limiting and did not require discontinuation as the dominant outcome in reported cohorts. Rotating injection sites is the standard mitigation strategy used in subcutaneous peptide trials and remains the first practical management step.
There is no published data specifically characterizing whether refrigerating the solution before injection (as some practitioners suggest for insulin site reactions) reduces SS-31 injection-site discomfort. Any such recommendation exists below the level of clinical evidence.
Systemic Safety: Heart, Kidney, and Liver Signal Review
Cardiac: SS-31 was studied specifically because of proposed mitochondrial cardioprotection. No proarrhythmic or direct cardiotoxic signal has emerged in published data. In PROGRESS-HF, the intervention targeted heart failure pathology, and no worsening cardiac events attributable to the peptide were highlighted.
Renal: Preclinical models (including ischemia-reperfusion injury models in rodents) have studied SS-31 as a renal protectant, not a nephrotoxin. Clinical trial data have not flagged creatinine elevation or GFR decline as an SS-31 adverse signal. That said, no dedicated renal pharmacokinetic study in humans with established chronic kidney disease has been published that allows confident dose adjustment guidance.
Hepatic: No pattern of elevated transaminases or hepatic injury has appeared in published trial safety tables. This is reassuring but limited by trial duration and size.
The honest caveat: A compound tested in hundreds of people over 24 weeks will not reliably detect adverse events with incidence below roughly 1 to 2 percent, or events that require years of exposure to manifest. Absence of a signal is not equivalence to proven safety for long-term use.
Formulation and Stability: The Hidden Risk Factor
This is the section most competitors skip entirely.
SS-31 is a tetrapeptide containing a dimethylated tyrosine residue and a free amine terminus. Like most small peptides, it is vulnerable to:
- Oxidation of the aromatic dimethyltyrosine residue. Oxygen exposure, especially at elevated temperatures or in the presence of trace metal ions (copper, iron), can oxidize this residue. The oxidized product has a different molecular weight and potentially altered receptor binding. An oxidized peptide is not the same compound that was tested in trials.
- Hydrolysis at peptide bonds in aqueous solution, accelerated by temperature and extreme pH. Reconstituted SS-31 should be used promptly or stored per validated conditions. Most compounded peptide guidance recommends refrigeration after reconstitution and use within days to a week, but formal stability kinetics for research-grade SS-31 at varying temperatures are not publicly documented in peer-reviewed literature, so specific day counts would be fabricated precision.
- Aggregation and particulate formation, which increases injection risk and alters pharmacokinetics.
The chemistry behind the storage rule: The dimethyltyrosine residue contains a phenolic hydroxyl group. Phenols are susceptible to one-electron oxidation to phenoxy radicals, which can then react with molecular oxygen to form quinone derivatives. This reaction is catalyzed by light and trace metals. Amber vials and refrigerated storage reduce both light exposure and reaction kinetics. Bacteriostatic water (containing benzyl alcohol) can slow microbial growth but does not prevent chemical oxidation of the peptide itself.
Practical check: A correctly prepared SS-31 solution should be clear and colorless. Yellow or amber coloration of the reconstituted solution, visible particulates, or a precipitate are signs of degradation or contamination. Do not use a vial showing any of these characteristics.
Honest Head-to-Head: SS-31 vs. Alternatives for Mitochondrial Support
| Feature | SS-31 (Elamipretide) | MitoQ | CoQ10 (Ubiquinol) | NAD+ Precursors (NMN/NR) |
|---|---|---|---|---|
| Route | Subcutaneous injection | Oral | Oral | Oral |
| Primary target | Cardiolipin, inner mitochondrial membrane | Mitochondrial matrix (electron carrier) | Electron transport chain | NAD+ biosynthesis |
| Human RCT safety data | Yes (hundreds of participants, weeks to months) | Limited RCT data | Extensive, decades | Growing, mostly short-term |
| FDA approval status | Not approved | Not approved (supplement) | Not approved (supplement) | Not approved (supplement) |
| Common side effects | Injection-site reactions (frequent), systemic effects (infrequent) | GI upset at high doses | GI upset at high doses | Generally well tolerated; flushing with some forms |
| Long-term safety data | Limited (under 12 months in humans) | Limited | Extensive | Limited |
| Where SS-31 loses | Requires injection, not approved, higher sourcing/purity risk, costlier | Oral convenience, lower barrier | Decades of safety record, low cost | Oral, accessible, growing evidence base |
| Where SS-31 has an advantage | More specific mechanistic target; most disease-context trial data of this group | Mitochondria-targeted delivery | Well-characterized efficacy in deficiency states | Broad metabolic effects |
Honest verdict: For most people without a diagnosed mitochondrial disorder, CoQ10 or NAD+ precursors have a better safety track record and are far easier to access safely. SS-31 has a more specific mechanistic rationale, but the injection requirement, sourcing complexity, and regulatory status mean the risk-benefit calculation is less favorable for general wellness use than most SS-31 content acknowledges.
Operational Label Literacy: How to Read an SS-31 COA
When evaluating any SS-31 product intended for injection, a certificate of analysis should contain all of the following. If any element is missing, treat the COA as incomplete.
| COA Element | What to Look For | Why It Matters |
|---|---|---|
| HPLC purity | 98% or higher by area | Lower purity means unknown impurities that carry their own biological effects |
| Mass spectrometry (MS) | Confirmed molecular weight matching SS-31 free base (~638.8 g/mol) or its acetate salt | Confirms the correct sequence was synthesized; rules out truncation errors |
| Endotoxin (LAL test) | Below 1 EU/mg for injectable use | Endotoxins cause fever and systemic inflammation; not detectable by appearance |
| Residual solvents | Within USP Class 2 or Class 3 limits | Synthesis residuals including DMF or acetonitrile are toxic at sufficient concentrations |
| Sterility (if applicable) | Sterility test passed or 0.22 micron filtered and aseptically filled | Non-sterile injectables risk abscess and systemic infection |
| Water content (Karl Fischer) | Reported; low moisture reduces degradation during storage | High moisture accelerates hydrolysis of peptide bonds |
Reconstitution math: A 10 mg vial reconstituted with 2 mL bacteriostatic water yields a 5 mg/mL solution. A 40 mg dose (as used in MMPOWER-3) would require 8 mL of that solution, which is a large subcutaneous volume and suggests either a higher concentration or multiple injection sites. If a supplier or protocol presents the dose without specifying concentration and volume, that is a practical safety gap you should close before use.
Who Should Not Use SS-31
- People who are pregnant or breastfeeding (no adequate safety data).
- People with known hypersensitivity to any component of the formulation.
- People who cannot source a product with a complete COA as described above.
- People managing conditions for which an approved therapy exists, without first discussing SS-31 with a supervising physician.
- People under 18, given the absence of pediatric pharmacokinetic data outside the narrow TAZPOWER enrollment criteria.
FAQ
What are the most common SS-31 peptide side effects?
In human trials, SS-31 (elamipretide) has most commonly caused injection-site reactions including pain, erythema, and induration. Systemic adverse effects have been infrequent and generally mild in published Phase I and II data. Fatigue and nausea were reported at low rates in some cohorts.
Has SS-31 been tested in humans for safety?
Yes. SS-31, under the clinical name elamipretide, has completed Phase I, Phase II, and Phase III trials. The PROGRESS-HF and MMPOWER trials are the largest human safety datasets publicly available, involving hundreds of participants over weeks to months.
Is injection-site pain from SS-31 serious?
Injection-site reactions are the most consistently reported adverse effect but have been rated mild to moderate in published trials. No serious injection-site events requiring discontinuation were the dominant pattern in MMPOWER and PROGRESS-HF safety summaries.
Can SS-31 cause kidney damage?
There is no established clinical evidence that SS-31 causes kidney injury. Preclinical and some clinical work has studied it as a renal-protective agent. However, long-term human renal safety data beyond 12 months is limited, so this question remains open.
What happens if SS-31 peptide degrades before use?
Degraded SS-31 may contain oxidized or aggregated fragments with unknown biological activity. A degraded vial typically shows visible particulates, yellow discoloration, or a pH shift. Using degraded peptide introduces unpredictable impurities and undermines any safety inference from clinical trial data.
Does SS-31 interact with common medications?
No formal drug-interaction studies in humans have been published for SS-31 in a research-compound context. The MMPOWER trial enrolled patients on standard heart failure regimens without reported major interactions, but this is not a substitute for a thorough drug-interaction review with a clinician.
Is SS-31 FDA approved?
No. As of May 2026, SS-31 (elamipretide) is not FDA approved for any indication. Stealth BioTherapeutics received a Complete Response Letter for the Barth syndrome NDA in 2023, citing manufacturing and additional efficacy concerns.
How does SS-31 compare to MitoQ or CoQ10 for mitochondrial support?
SS-31 targets cardiolipin on the inner mitochondrial membrane via a specific electrostatic and aromatic mechanism, whereas MitoQ and CoQ10 work primarily as electron carriers. SS-31 has more human trial data in serious disease, but MitoQ and CoQ10 have decades of real-world safety data and are orally available.
What purity should I look for on an SS-31 certificate of analysis?
A credible COA should report HPLC purity at or above 98%, mass spectrometry confirmation of the correct molecular weight (638.8 g/mol for the free base tetrapeptide), endotoxin testing below 1 EU/mg for injectable use, and residual solvent analysis. Any COA missing mass spec confirmation is incomplete.
Can women or people who are pregnant use SS-31?
There are no adequate human safety data on SS-31 in pregnancy or lactation. Animal reproductive toxicology data are limited. Use in pregnancy is not supported by current evidence.
What dose of SS-31 was used in human trials?
The MMPOWER-3 trial used subcutaneous elamipretide 40 mg per day. Earlier Phase I work tested intravenous doses in ascending ranges. Research-compound protocols often cite subcutaneous doses in a similar range, but these are not FDA-supervised and carry additional uncertainty.
Sources
- Karaa A, et al. "A randomized crossover trial of elamipretide in adults with primary mitochondrial myopathy." Journal of Inherited Metabolic Disease. 2020;43(4):695-704.
- Daubert MA, et al. "Novel Mitochondria-Targeting Peptide in Heart Failure Treatment: A Randomized, Placebo-Controlled Trial of Elamipretide." Circulation: Heart Failure. 2017;10(12):e004389.
- Szeto HH. "First-in-class cardiolipin-protective compound as a therapeutic agent to restore mitochondrial bioenergetics." British Journal of Pharmacology. 2014;171(8):2029-2050.
- Birk AV, et al. "The mitochondrial-targeted compound SS-31 re-energizes ischemic mitochondria by interacting with cardiolipin." Journal of the American Society of Nephrology. 2013;24(8):1250-1261.
- U.S. Food and Drug Administration. Complete Response Letter: Elamipretide NDA (Barth Syndrome). 2023. Available at: FDA.gov.
- Thompson WR, et al. "A phase 2/3 randomized clinical trial followed by an open-label extension to evaluate the effectiveness of elamipretide in Barth syndrome, a genetic disorder of mitochondrial cardiolipin metabolism." Genetics in Medicine. 2021;23(3):471-478.
- Szeto HH, Schiller PW. "Novel Therapies Targeting Inner Mitochondrial Membrane: From Discovery to Clinical Development." Pharmaceutical Research. 2011;28(11):2669-2679.
- Bharat Bhatt, et al. PROGRESS-HF trial results presented at American Heart Association Scientific Sessions. Published summaries available via ClinicalTrials.gov NCT02914665.
Footer Disclaimers
Platform: This page is published by FormBlends for informational and educational purposes only. FormBlends is not a licensed pharmacy, medical practice, or healthcare provider. Nothing on this page constitutes medical advice, diagnosis, or treatment recommendation.
Research Compound: SS-31 (elamipretide) is not approved by the FDA or any equivalent regulatory authority as of the date of publication. Where available outside supervised clinical trials, it is a research compound. Its use outside an IRB-approved protocol or physician-supervised compounding program is not endorsed by FormBlends.
Results: Individual outcomes vary. Safety and efficacy data cited on this page derive from clinical trials conducted under controlled conditions with pharmaceutical-grade material and clinical oversight. These conditions may not replicate those of any individual's use.
Trademark: Elamipretide, Bendavia, and MTP-131 are trade names associated with their respective holders. FormBlends has no affiliation with Stealth BioTherapeutics or any other elamipretide developer. Product and company names are used solely for factual identification.